Olema Pharmaceuticals, Inc. business relationships
Companies named in Olema Pharmaceuticals, Inc.’s 10-K filed 2026-03-16, and public companies whose annual reports name Olema Pharmaceuticals, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 12 / 100 Top 2% in its category
- Agent readiness
- 30 / 100
- AI adoption
- 0 / 100
Named in Olema Pharmaceuticals, Inc.’s annual report 4
“The Novartis Amendment, among other things, expanded the Company's clinical collaboration with Novartis, increasing the size of the ongoing Phase 1/2 study testing palazestrant in combination with ribociclib to approximately 60 patients.” SEC filing
“We have established clinical collaborations with both Novartis and Pfizer and we intend to continue evaluating opportunities to work with partners that meaningfully enhance our capabilities with respect to the development and commercialization of our product candidates.” SEC filing
“Clinical Collaboration and Supply Agreement with Novartis” SEC filing
“Clinical Trial Collaboration and Supply Agreement with Pfizer” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.